Basel, Switzerland, May 30, 2007 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today that Swissmedic granted Janssen-Cilag AG, a Johnson & Johnson company, accelerated assessment of the planned market authorization application (“Beschleunigtes Zulassungsverfahren”) for ceftobiprole for the treatment of complicated skin and soft tissue structure infections.
